Twenty years ago, Columbia scientists created a way to make neurons in a dish, a discovery that has led to clinical trials of an experimental drug that may slow the progression of ALS.
Using EEG to identify covert consciousness in unresponsive brain-injured patients could help predict which ones may recover, find researchers at Columbia and NewYork-Presbyterian.
Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
A gene called FMNL2 may explain why people with hypertension, diabetes, heart disease, or obesity have a greater risk of developing Alzheimer's disease.
Neurologist Scott A. Small participated in a Kavli Foundation roundtable on the link between the brain's ability to make new cells and age-related memory loss.
In most cases of ALS, a toxin released by cells that normally nurture neurons in the brain and spinal cord can trigger loss of the nerve cells affected in the disease, report Columbia researchers.
CUMC researchers have identified a gene that appears to play a major role in motor neuron degeneration in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.